Business Wire

GE-RENEWABLE-ENERGY

13.2.2020 10:02:09 CET | Business Wire | Press release

Share
EU Funding Accelerates GE’s Development of World’s First SF6-free 420 kV Circuit-Breaker

GE Renewable Energy’s Grid Solutions business (NYSE-GE) has been awarded €2.2 million through the European Commission’s LIFE climate action program to help fund the development of a sulfur hexafluoride (SF6 )-free, 420 kiloVolt (kV) 63 kilo Amps (kA) gas-insulated substation (GIS) circuit-breaker.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005296/en/

The new circuit-breaker will rely on GE’s industry-leading “Green Gas for Grid”—or “g3” (pronounced “g- cubed”)—technology, resulting in the same high performance and compact size as a traditional SF6 -insulated circuit-breaker, but with a gas mass having more than a 99% reduced CO₂ equivalent value. Upon completion in 2022, the g3 circuit-breaker is expected to be the first SF6 -free 420 kV gas-insulated substation circuit-breaker in the world.

A circuit-breaker is protective equipment used to cut power in case of a problem on the grid. High-voltage 420-kV circuit-breakers are found at electrical substations on long-distance transmission networks.

Due to its strong insulating and arc-quenching properties, SF6 is widely used in substation equipment with the transmission industry accounting for approximately 80% of the world’s usage. Identified as the world’s most potent greenhouse gas by the 1997 Kyoto Protocol, SF6 is estimated to contribute 23,500 times more emissions than CO₂ if leaked and can remain in the atmosphere for up to 3,200 years.

“Our g3 technology is a game-changing alternative to SF6 for high-voltage equipment and is part of GE’s broader efforts to help the electric transmission and distribution industry reduce its greenhouse gas emissions,” said Vera Silva, Chief Technology Officer at GE’s Grid Solutions.

“Because 420 kV is the highest voltage level used in most European countries, a proven g3 –insulated 420 kV circuit-breaker will demonstrate that g3 technology can be applied to other high-voltage levels, as well as all other gas-insulated substation components, such as disconnectors, earthing switches, voltage transformers,” said Yannick Kieffel, Grid Solutions’ Materials and Eco Design Team Leader and Project Leader for the EU-funded g3 project.

Currently, GE offers the following g3 products: live tank circuit-breakers and gas-insulated substations up to 145 kV, gas-insulated lines up to 420 kV and instrument transformers up to 245 kV.

“This project is a great fit for our recent round of LIFE financial awards due to its potential impact on Europe’s transition to a more sustainable and low-carbon future,” said Angelo Salsi, LIFE Programme Head of Unit at the Executive Agency for Small and Medium-sized Enterprises (EASME). “The LIFE program is one of the most efficient and well known EU funding mechanisms that has supported nature, the environment and climate action for over 25 years. We look forward to the positive ripple effect this project will have across Europe over the next decade and beyond.”

For the full press release on the g3 EU-funded circuit-breaker project LIFE18 CCM/FR/001096 LIFE GRID , click here .

GE’s Grid Solutions

Grid Solutions, a GE Renewable Energy business, serves customers globally with over 17,000 employees in approximately 80 countries. Grid Solutions helps enable utilities and industry to effectively manage electricity from the point of generation to the point of consumption, helping to maximize the reliability, efficiency and resilience of the grid. https://www.gegridsolutions.com/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye